key: cord-1033718-vb8z21rv
authors: Lai, Xinyuan; Yu, Yanying; Xian, Wei; Ye, Fei; Ju, Xiaohui; Luo, Yuqian; Dong, Huijun; Zhou, Yi-Hua; Tan, Wenjie; Zhuang, Hui; Li, Tong; Liu, Xiaoyun; Ding, Qiang; Xiang, Kuanhui
title: Identified human breastmilk compositions effectively inhibit SARS-CoV-2 and variants infection and replication
date: 2022-03-22
journal: iScience
DOI: 10.1016/j.isci.2022.104136
sha: 040c8ccacdbdb8b03421590b058444b42c554c03
doc_id: 1033718
cord_uid: vb8z21rv

The global pandemic of COVID-19 caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection confers great threat to the public health. Human breastmilk is a complex with nutritional composition to nourish infants and protect them from different kinds of infectious diseases including COVID-19. Here, we identified lactoferrin (LF), mucin1 (MUC1) and α-lactalbumin (α-LA) from human breastmilk inhibit SARS-CoV-2 infection using a SARS-CoV-2 pseudovirus system and transcription and replication-competent SARS-CoV-2 virus-like-particles (trVLP). Additionally, LF and MUC1 inhibited multiple steps including viral attachment, entry and post-entry replication, while α-LA inhibited viral attachment and entry. Importantly, LF, MUC1 and α-LA possessed potent antiviral activities towards variants such as B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.1 (kappa). Taken together, our study provides evidence that human breastmilk components (LF, MUC1 and α-LA) are promising antiviral and potential therapeutic candidates warranting further development or treating COVID-19.

It confers a great threat to global public health since the pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 in the outbreak in late 2019. SARS-CoV-2 shows close phylogenetic J o u r n a l P r e -p r o o f relationship with SARS-CoV causing outbreak in 2002 (Meo et al., 2020) . The high mortality in the pandemic worldwide has caused the collapse of health systems in many countries, especially in developing countries (Guan et al., 2020) . In addition, the ancestral virus has evolved several viral variants in the long pandemic (Leung et al., 2021; Liu et al., 2021; . These variants may have potentially altered viral transmission, pathogenicity, efficacy of drug treatment as well as neutralizing capacity of vaccine elicited antibodies (Gu et al., 2020; Ren et al., 2021; Starr et al., 2020; Volz et al., 2021) . With this situation, it is urgent to develop effective drugs to treat this disease.

As reported previously, COVID-19 pandemic also confers a concern of the safety of breastmilk feeding at the beginning of its outbreak (Dong et al., 2020; Gross et al., 2020; Lugli et al., 2020; Unger et al., 2020; Yu et al., 2020) . Despite detection of SARS-CoV-2 RNA in human breastmilk, it is still unclear if SARS-CoV-2 could transmit from mothers who have been infected to infants through breastfeeding (Gross et al., 2020) .

Several lines of evidence in the clinical studies showed that SARS-CoV-2 can't transmit to infants via breastmilk (Chambers et al., 2020; Lugli et al., 2020; Perrone et al., 2020; Unger et al., 2020; Yu et al., 2020) . The World Health Organization and other organizers who drafted several guidelines still continue recommend breastfeeding even if the mothers have the symptoms of COVID-19 (WHO, 2020; Wszolek et al., 2021) .

However, more information is needed to support breastfeeding.

Human milk is uniquely suited to feed infants due to its nutritional composition and bioactive factors promoting antimicrobial and immunomodulatory effects (van der J o u r n a l P r e -p r o o f Strate et al., 2001) . Breastmilk inhibits several viral infections, such as human immunodeficiency virus (HIV), cytomegalovirus (CMV) and dengue virus. In addition to those enveloped viruses, breastmilk also inhibits many non-enveloped viruses like rotavirus, enterovirus and adenovirus (Kell et al., 2020; van der Strate et al., 2001) . The lactoferrin (LF), an important component in breastmilk, suppresses SARS-CoV and SARS-CoV-2 through blocking viral binding to heparan sulfate proteoglycans, raising the possibility that human breastmilk can also suppress SARS-CoV-2 infection (Lang et al., 2011; Mirabelli et al., 2021; Yanmei Hu 2021) . Indeed, we previously confirmed that human breastmilk significantly inhibits SARS-CoV-2 and its related pangolin coronavirus (GX_P2V) infection. Importantly, we observed significantly higher anti-SARS-CoV-2 effects of breastmilk than LF mono-treatment, indicating that other important factors in breastmilk may contribute to the inhibition of SARS-CoV-2 infection and replication . Thus, it remains an urgent need to identify them in breastmilk that have the potential to suppress SARS-CoV-2 infection.

Breastmilk is a mixture of diverse nutrients that protect infants from different kinds of disease. It contains more than 400 different proteins and many of them exhibit antimicrobial activity (Ballard and Morrow, 2013) . Proteins in human milk can be divided into three groups, caseins, mucin and whey proteins. These bioactive proteins from the whey fraction include LF, mucins (MUC1 and MUC4), α-lactalbumin (α-LA), lactadherin, lactoperoxidase, IgA and lysozyme (LZ) and so on (Ballard and Morrow, 2013; Florisa et al., 2003) . LF is an iron-binding protein with two molecules of Fe 3+ ion per protein and rich in human milk (1-2 g/L in mature milk, 5-10 g/L in colostrum), J o u r n a l P r e -p r o o f whereas relatively lower level is present in other species such as bovine milk (0.02-0.3 g/L in mature milk, 2-5 g/L in colostrum) (Florisa et al., 2003) . As reported previously, LF is an important component to protect infants from microbial infection (Florisa et al., 2003; van der Strate et al., 2001) . LZ is also known to be a key protein inhibiting bacteria and rich in human milk (0.4 g/L). Lactadherin, a 46 KDa mucin associated protein, was reported that it displays high viral receptor affinity and specific antirotavirus activity (Florisa et al., 2003) . MUC1, mostly present in the fat globule membrane (cream fractions, about 1.32-1.41 g/ml) with very low level in skim milk (about 50 ug/ml), has the antiviral activity to inhibit influenza virus infection (McAuley et al., 2017; Mthembu et al., 2014) . In addition, human milk also contains antibodies like immunoglobulin (Ig)G and IgA which show antiviral activity (Ejemel et al., 2020; Florisa et al., 2003) . Therefore, these findings inspired us to identify the anti-SARS-CoV-2 components in breastmilk and explore the underlying mechanisms.

Here, we aimed to identify the potential factors of human breastmilk in suppressing SARS-CoV-2 infection by combing biochemical fractionation, activity assays and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis (Hu et al., 2014) . Antiviral activities of individual fractions from breastmilk were measured in multiple cell lines (Huh7.5, Vero E6 and Caco-2-N) infected by SARS-CoV-2 pseudovirus and trVLP system, respectively . Remarkably, we identified LF, MUC1 and α-LA with strong inhibitory effects on SARS-CoV-2 infection together with different variants by blocking viral entry and post-entry replication. These findings shed light on the important roles of LF, MUC1 and α-LA derived from human milk and J o u r n a l P r e -p r o o f provide the basis for the rational design and development of antiviral drugs.

To identify the potential factors of human skimmed milk in suppressing SARS-CoV-2 infection, we designed the following experimental strategy ( Figure 1A) . Firstly, we performed biochemical fractionation by ion exchange chromatography. Then individual fractions were subjected to antiviral activity assays ( Figure 1B to 1D) , where Vero E6 cells were infected with 650 TCID50/well of SARS-CoV-2 pseudovirus with the addition of fractionated samples in the media. One day post infection, we measured their inhibitory effects on SARS-CoV-2 infection ( Figure 1E ). The fraction that retained the highest activity was analyzed by LC-MS to identify the potential factors from the skimmed milk shown in Figure 1A . Briefly, we first processed skimmed milk for ammonium sulfate precipitation to remove most proteins without antiviral activity.

After precipitation with different concentrations of ammonium sulfate, we assayed the supernatants for their inhibition of viral infection. We found that most of the ingredients with antiviral activity were retained in the supernatant with the use of 1 M ammonium sulfate. After precipitation, the samples were fractionated by sequential ion exchange chromatography. The active fractions from each column step were pooled, concentrated, dialyzed, and loaded onto the next column. We fractionated the separated supernatant by using cation exchange chromatography and collected both the flowthrough (SP1) J o u r n a l P r e -p r o o f and column-bound fractions eluted with a linear salt gradient from 0 M to 1 M of NaCl (SP2 and SP3) ( Figure 1B) . We observed highest antiviral activity at fraction SP3 ( Figure 1E) , which was concentrated, dialyzed and subjected further to anion exchange chromatography. After collection of both the flowthrough (Q1) and column-bound fractions eluted with 1M NaCl (Q2) (Figure 1C) , we found the antiviral activity was retained at fraction Q2 but not Q1. Next, we run the Q2 fraction by SDS-PAGE ( Figure   1D ), and the stained protein bands between 70-100 kDa were excised and processed for mass spectrometric identifications. Eventually, we found that LF in skimmed milk was a potential factor for SARS-CoV-2 inhibition ( Figure 1F and Figure S1 to S4).

As reported previously, LF might not be the effective factor alone in breastmilk and there might be other components showing anti-SARS-CoV-2 activity. Previous reports showed that some factors, such as MUC1, MUC4, lactadherin, α-LA, etc., have antimicrobial activity (Ballard and Morrow, 2013; Florisa et al., 2003) . To identify the factors that also inhibit SARS-CoV-2 infection, we mixed the MUC4, MUC1, α-LA, lactadherin and LF with 650 TCID50/well of luciferase-expressing SARS-CoV-2 pseudovirus, respectively. Then, the mixture was used to infect Vero E6 cell for 24h. MUC4 (Figure 2A ) and lactadherin ( Figure 2D ) showed no suppression of SARS-CoV-2 pseudovirus infection. Interestingly, MUC1 (0.25 μg/ml, Figure 2B ), α-LA (0.25 mg/ml, Figure 2C ) and LF (0.25 mg/ml, Figure 2E ) showed a dramatic inhibition of SARS-CoV-2 pseudovirus infection. In addition, we also used the GFP expressing SARS-CoV-2 pseudovirus to verify the inhibition activity of LF, MUC1 and α-LA in both Huh7.5 and Vero E6 cell lines. As shown in Figure 2F to 2H, all of them J o u r n a l P r e -p r o o f suppressed GFP expression, indicating that these factors in skimmed milk could inhibit SARS-CoV-2 infection. Thus, we identified that these three components in breastmilk inhibit SARS-CoV-2 pseudovirus infection.

To further explore to what extent these factors inhibit SARS-CoV-2 infection, we evaluated the effects of LF, MUC1 and α-LA on SARS-CoV-2 infection in a cell culture system of transcription-and replication-competent SARS-CoV-2 virus-like-particles (trVLP), which expresses a reporter gene (GFP) replacing viral nucleocapsid gene (N) and also could complete viral life cycle in the cells expressing N protein .

Caco-2-N cells were infected with trVLP (MOI=1) and treated with LF, MUC1 and α-LA at different concentrations for 96 h ( Figure 3A ). Subsequently, we carried out RT-qPCR analysis of cell lysates, in which a dramatic decrease in the levels of SARS-CoV-2 RNA upon treatment was observed ( Figure 3B) . Furthermore, GFP expression as a marker of viral replication revealed that both LF and MUC1 significantly suppressed SARS-CoV-2 replication ( Figure 3C ). We observed relatively lower inhibitory effect of α-LA on SARS-CoV-2 infection, because some GFP expression was even seen at the concentration of 2 mg/ml. Consistent with the GFP results, western blot analysis of the cell lysates showed that MUC1 and LF could significantly suppress the S protein expression of SARS-CoV-2 ( Figure 3D ). The α-LA at a high concentration of 2 mg/ml could also suppress SARS-CoV-2 infection.

In addition, we examined whether LF orthologs from other species possess inhibitory effect on SARS-CoV-2 infection. We included the inhibitory effect of recombinant human LF (rLF), human isolated LF (hLF), bovine LF (bLF) and goat LF (gLF) on SARS-CoV-2 infection assays with the skimmed milk (fraction A17) as a positive control. Firstly, we analyzed the amino acid sequence of LF from human, bovine and goat and found that their sequences are quite different, indicating a potential nonidentical antiviral activity ( Figure 4A) . Then, we utilized 650 TCID50/well of SARS-CoV-2 pseudovirus to infect Vero E6 cells treated with rLF, hLF, bLF, gLF and A17 for 24h. Afterwards, we measured the luciferase reporter activity and found that all the LFs and A17 significantly suppressed SARS-CoV-2 pseudovirus infection regardless of their origin ( Figure 4B) . Consistent with the pseudovirus system, the data from the trVLP system supported the inhibition of SARS-CoV-2 infection and replication by all the LFs as well when both the mRNA levels ( Figure 4C ) and GFP expression ( Figure 4D ) were down-regulated. Western blot analysis of the cell lysates showed that rLF and bLF significantly suppressed SARS-CoV-2 S protein expression ( Figure 4E ). In addition, we found that gLF at high concentrations (i.e., 2 mg/ml) was toxic to cells ( Figure 4F) , while other LFs showed undetectable toxicity. When treating the cells at different concentrations and infecting them with trVLP (MOI=1) for 96 h, we found that EC50 value of gLF for suppressing SARS-CoV-2 infection is low.

However, CCK8 analysis showed that gLF at higher concentrations exhibited more robust cytotoxicity to Caco-2-N cells with CC50 of 5.64 mg/ml ( Figure 4G ). Together, we have shown that LF, MUC1 and α-LA from human breastmilk are able to suppress Figure 6A (pre-infection treatment), in which these factors were washed away prior to viral infection. We observed a significant decrease of viral RNA in those groups treated by MUC1, α-LA, rLF, hLF, bLF and A17 ( Figure 6B) . Similarly, cells treated with these factors showed nearly no viral replication associated GFP expression at all ( Figure 6C) . We also performed an infection using pseudovirus ( Figure S6A ) and found comparable reduction of the luciferase expression in Vero E6 and Huh7.5 cells ( Figure S6B ). Taken together, these data indicated that MUC1, LF and α-LA might block viral attachment and entry.

Next, we tested their effects on the post-infection experiment as shown in Figure 6D .

In these experiments, we found that reduced level of the viral RNA and GFP expression upon treatment with MUC1 and LF, while cells treated with α-LA showed comparable level of RNA and GFP expression to controls ( Figure 6E and 6F). In line with these data, we observed significantly lower luciferase expression of pseudovirus ( Figure S6C) J o u r n a l P r e -p r o o f after MUC1 and LF treatment, while cells treated with α-LA only exhibited a minor reduction ( Figure S6D ). Given that the pseudovirus was packaged based on the VSV, the post-entry replication usually reflects VSV replication. Then, we included the VSV as a control in the designed experiment ( Figure S6C ). As expected, these factors also inhibited VSV replication ( Figure S6E ). These data suggested that both LF and MUC1, but not α-LA, can suppress SARS-CoV-2 post-entry replication.

In addition, we also examined whether MUC1, LF and α-LA can suppress viral entry.

We infected the Caco-2-N cells with trVLP and Huh7.5 and Vero E6 cells with pseudovirus at 4 ℃ for 1 h, respectively. Then, we washed the virus away and refreshed the media supplemented with these factors until the end point of infection. Interestingly, all these factors showed potent antiviral activity as evidenced by the dramatic reduction of the SARS-CoV-2 RNA ( Figure 6G ) and luciferase activity levels ( Figure S6F ).

Together, these data suggested that MUC1, LF and α-LA suppress SARS-CoV-2 entry step of viral life cycle.

Next, we sought to determine if MUC1, LF and α-LA can interfere with the interaction of ACE-2 and S protein by performing the affinity assays. As shown in Figure 7A and 7B, LF and MUC1 didn't block the interaction of ACE-2 and S protein, indicating that they suppress SARS-CoV-2 infection by mechanisms independent of the ACE-2 pathway. Interestingly, our assays revealed that α-LA interfered with the association J o u r n a l P r e -p r o o f between SARS-CoV-2 spike protein and ACE-2, as evidenced by high absorbance after α-LA treatment at a low concentration of 0.25 mg/ml ( Figure 7C ).

HSPG (Lang et al., 2011) . To determine its potential involvement in the inhibition of SARS-CoV-2 infection, we treated the cells with LF combined with different concentrations of heparin. We found that the inhibitory effect of LF and MUC1 on SARS-CoV-2 decreased with the addition of heparin in a concentration dependent manner, to the deep when 10 U/ml of heparin was added in both Huh7.5 ( Figure 7D and 7F) and Vero E6 ( Figure 7E and 7G) cells. However, when the level of heparin was increased to 100 U/ml, we found a more potent inhibitory effect, indicating that heparin could interfere the inhibitory effect of LF on SARS-CoV-2 infection.

To further confirm that LF and MUC1 interact SARS-CoV-2 attaching HSPG, we also performed new experiments in the trVLP infected Caco-2-N cells as designed in Figure S7A . As shown, we also found that MUC1 ( Figure S7B ) and LF ( Figure S7C) rather than α-LA ( Figure S7D ) could interfere heparin's inhibition of SARS-CoV-2 infection. These data suggested that inhibition of viral attachment to HSPG contributes, at least partially, to LF suppressing SARS-CoV-2 infection.

To determine whether these factors are effective in inhibiting SARS-CoV-2 variants, we constructed and packaged four SARS-CoV-2 mutants (i.e., B. (Figure 8E) ). These results suggested that MUC1, rLF and α-LA are able to suppress the infection and replication of SARS-CoV-2 variants as well.

In this study, we developed an experimental workflow combing biochemical fractionation, LC-MS and SARS-CoV-2 pseudovirus system profiling that allows effective screening the potential components in human breastmilk for inhibiting SARS- breastfeeding, SARS-CoV-2 positive in breastmilk still confers a great concern of the safety of breastfeeding to infants from SARS-CoV-2 infected mothers (Chambers et al., 2020; Chen et al., 2020; Dong et al., 2020; Zhu et al., 2020) . Chambers et al. reported that they collected the positive breastmilk from 18 infected women and tested the infectivity in the cell culture system (Chambers et al., 2020) . They didn't find any viral RNA positive in the experiments, indicating that SARS-CoV-2 in the breastmilk can't infect and transmit. Consistent with this, previously we have also showed that even we added the live virus at relatively high concentrations in the breastmilk, the virus still could not infect the cells, suggesting highly potent activity of human breastmilk in anti-SARS-CoV-2 infection . Therefore, the international guidelines and World Health Organization still strongly recommend to continue breastfeeding even if mothers have symptoms of COVID-19 because breastfeeding unquestionably reduces neonatal and infant mortality and provides numerous lifelong health and brain development advantages to the infants (WHO, 2020; Wszolek et al., 2021) . In this study, we successfully identified LF, MUC1 and α-LA in the milk with highly effective antiviral activity to SARS-CoV-2 infection. Interestingly, the EC50 values of these factors are much lower than their concentrations in human breastmilk, suggesting the strong antiviral activity of human breastmilk for SARS-CoV-2 infection. As a result, hardly any live SARS-CoV-2 virus in the milk can infect and transmit to infants during the breastfeeding. For example, the EC50 value of LF to SARS-CoV-2 is 0.08 mg/ml, while the concentration of LF in human mature breastmilk and colostrum is 1-2 mg/ml and 5-10 mg/ml, respectively. In other words, such high LF concentrations in breastmilk J o u r n a l P r e -p r o o f effectively inhibits potential SARS-CoV-2 infection and transmission. This analysis suggested that breastfeeding may be safe for infants whose mother are infected with SARS-CoV-2, if the breastmilk is pumped into sterile containers and feed infants with isolation from their mother. Thus, our data provides strong evidence of the importance of breastmilk in antiviral property, which strongly supports the guidelines for managements of birth and breastfeeding during SARS-CoV-2 pandemic. However, further studies are still warranted to confirm the safety of breastfeeding to infants from SARS-CoV-2 infected mother.

SARS-CoV-2 is able to mutate simply in its RNA genome during the infection, leading to viral escape from antibody neutralization, vaccination, and other drugs targeting the interaction between S protein and ACE-2 (Liu et al., 2021) . Surprisingly, we provided evidence that LF, MUC1 and α-LA are still highly effective in inhibiting the currently transmitting mutants such as B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.1 (kappa). Therefore, we conclude that these factors from breastmilk can offer strong and broad-spectrum protection from SARS-CoV-2 infection.

It is noteworthy that LF, MUC1 and α-LA identified in our study are also safe and available in dietary supplement (Andreas et al., 2015) . All these factors were reported with antiviral activity and their expression was associated with viral infection (Florisa et al., 2003) . Reghunathan R et al. showed up-regulated expression of LF expression during SARS-CoV infection, which blocked viral attachment through HSPG (Reghunathan et al., 2005) . Moreover, Mirabelli C et al. reported that LF screened from the FDA approved drugs also inhibited SARS-CoV-2 to bind to the cells through J o u r n a l P r e -p r o o f competition with HSPG and also modulates innate immune responses to increase expression of interferon stimulated genes and TNFα (Mirabelli et al., 2021) . Similarly, our study also proved that LF from different species (such as bovine and goat) also inhibited SARS-CoV-2 attachment to HSPG and post-entry replication. LFs from human and bovine showed nearly no toxicity to all used cells like Huh7.5, Vero E6 and Caco-2-N cells. However, gLF could be toxic to cells at high concentration treatment, indicating variations from different species. Our previous study showed that skimmed milk can suppress the activity of RNA-dependent RNA polymerase of SARS-CoV-2 . Thus, further studies are required to elucidate the exact mechanism(s) of how LF inhibits SARS-CoV-2 infection and replication.

In addition, MUC1 is an important factor expressing in the lung airway maintaining 

While lactoferrin, mucin1 and α-lactalbumin identified from breastmilk in this study holds promising potential to be used as a clue for the safety of breastmilk feeding when mother infected with SARS-CoV-2, and also be developed as inhibitors of SARS-CoV-2 infection, there are a few limitations that need to be addressed before their further application. Firstly, this study was based on the in vitro cell models, which needed to J o u r n a l P r e -p r o o f be tested in vivo efficacy and toxicity. In addition, it would be helpful to test the efficacy of these factors in inhibiting viral infection of different variants from clinic.

Mechanistically, this study suggests that lactoferrin, mucin1 and α-lactalbumin interfere viral attachment, entry and post-entry replication. It would be important to identify host factors and innate immune response that these factors interact with to inhibit SARS-CoV-2 infection in the future. Scale bar represents 100 μm. Data are presented as mean ± SD and repeated at least three times (N = 3), **p < 0.01, ***p < 0.001, ****p<0.0001. PBS for three times. The cells were then added with fresh media with MUC1, α-LA, rLF, hLF, bLF and A17 treatment at 37 ℃ for 2 hours. After that, the supernatant was discarded and the cells were reloaded with fresh media and cultured for 48 hours. The J o u r n a l P r e -p r o o f cells were lysed and the viral RNA was detected by RT-qPCR. MUC1 (2 ug/ml), α-LA (a-lactalbumin, 2 mg/ml), rLF (recombinant lactoferrin, 2 mg/ml), hLF (human lactoferrin, 2 mg/ml), bLF (bovine lactoferrin, 2 mg/ml) and A17 (skimmed milk, 2 mg/ml). Scale bar represents 100 μm. Data are presented as mean ± SD and repeated at least three times (N = 3), ***p < 0.001, ****p<0.0001. See also Figure S6 . and (E) inhibition of SARS-CoV-2 pseudovirus infection. Huh7.5 and Vero E6 cells were treated with heparin for 10 min at the dosage of 0.1 U/ml, 1 U/ml, 10 U/ml and 100 U/ml. Then, 2 mg/ml LF was added to each group and incubated at 37℃ for 1h.

Vero E6 cells were treated with heparin for 10 min at the dosage of 0.1 U/ml, 1 U/ml, 10 U/ml and 100 U/ml. Then, 2 mg/ml LF was added to each group and incubated at 37℃ for 1h. The luciferase assay was performed to detect SARS-CoV-2 pseudovirus infection. Data are presented as mean ± SD and repeated at least three times (N = 3), **p < 0.01, ****p<0.0001. HSPG: heparan sulfate proteoglycans; LF: lactoferrin; MUC1: mucin 1. See also Figure S7 . 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Kuanhui Xiang (kxiang@bjmu.edu.cn)

All materials in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

Data reported on this paper will be shared by the lead contact upon request. The original sequencing datasets for trVLP of SARS-CoV-2 can be found on the Wuhan-Hu-1,

Table. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

The mature breastmilk produced one month after birth in 2017 was collected via pump into sterile containers after disinfecting nipples with 75% ethanol. Samples were frozen in aliquots at -80°C. The skimmed milk samples preparation was performed . In detail, the mature breastmilk was centrifuged for 15 min at 4,000  g at 4 °C.

The upper lipid was discarded and lower aqueous phase was collected and used for further experiments and analysis . Mothers were informed consent.

They were not infected with hepatitis B and C viruses and HIV. This study was approved by the ethics committees of the Medical Center.

HEK293T, Vero E6, Huh7.5 and Caco-2-N cells were maintained in Dulbecco's modified Eagle medium (DMEM, Gibco, China) supplemented with 10% fetal bovine J o u r n a l P r e -p r o o f serum (FBS) in a humidified 5% (vol/col) CO2 incubator at 37 ℃. All cell lines were tested negative for mycoplasma. Goat and cow whey proteins were purchased from Sigma (USA). The recombined lactoferrin (rLF), human lactoferrin (hLF) and bovine lactoferrin (bLF) were purchased from Sigma (USA). Lactadherin, a-lactalbumin were purchased from Sigma (USA). MUC1 encoding from Ala23 to Gly167 is expressed with a Fc tag at the C-terminus and purchased from Novoprotein (China).

Prof. Youchun Wang (National Institutes for Food and Drug Control, China) and Prof.

Ningshao Xia (Xiamen University), respectively. The trVLP and their mutants of B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.1 (kappa) expressing GFP replacing viral nucleocapsid gene (N) were used in this study . Caco-2-N cells were infected with the trVLP to amplify viruses . P5 to P10 were used in this study.

The viral production was performed as previously described . In detail, 

Vero E6 or Huh7.5 cells were seeded in a 24-well plate (80,000 cells per well) one day prior to viral infection. The cells were infected with viral inocula of 650 TCID50/well.

One day post infection (1dpi), the cells were lysed and the luminescence was measured according to the manufacturer's protocol. For trVLP, Caco-2-N cells were seeded in a 24-well plate (80,000 cells/well) one day prior to viral infection and infected with trVLP at multiplicity of infection (MOI) of 0.1. Three days post-infection, the mRNA levels of trVLP and GAPDH were determined by RT-qPCR.

Upon SDS-PAGE fractionation, the band of interest was excised and subjected to ingel trypsin digestion as previously described (Hu et al., 2014) . LC-MS analyses of J o u r n a l P r e -p r o o f protein digests were carried out on a hybrid ion trap-Orbitrap mass spectrometer (LTQ Orbitrap Velos, Thermo Scientific) coupled with nanoflow reversed-phase liquid chromatography (EASY-nLC 1000, Thermo Scientific). The capillary column (75 μm× 150 mm) with a laser-pulled electrospray tip (Model P-2000, Sutter instruments) was home-packed with 4 μm, 100 Å Magic C18AQ silicabased particles (Michrom BioResources Inc., Auburn, CA) and run at 250 nL/min with the following mobile phases (A: 97% water, 3% acetonitrile, and 0.1% formic acid; B: 80% acetonitrile, 20% water, and 0.1% formic acid). The LC gradient started at 7% B for 3 min and then was linearly increased to 37% in 40 min. Next, the gradient was quickly ramped to 90% in 2 min and stayed there for 10 min. Eluted peptides from the capillary column were electrosprayed directly onto the mass spectrometer for MS and MS/MS analyses in a data dependent acquisition mode. One full MS scan (m/z 400-1200) was acquired by the Orbitrap mass analyzer with R = 60,000 and simultaneously the ten most intense ions were selected for fragmentation under collisioninduced dissociation (CID).

Dynamic exclusion was set with repeat duration of 30 s and exclusion duration of 12 s. 

Caco-2-N, were seed in 24-well plates with 80,000 cells/well one day before the infection. LF (2 mg/ml), MUC1 (2 ug/ml) or α-LA (2 mg/ml) was mixed with trVLP J o u r n a l P r e -p r o o f (MOI=1) at 4℃ for 1h, respectively. The mixture was added into the cells and put at 4℃ for 2h to allow viral attachment to cells. After washing out of free virus, cell surface trVLP was extracted and quantified by RT-qPCR. For SARS-CoV-2 pseudovirus, Huh7.5 and Vero E6 cells were seed in 96-well plates with 20,000 cells/well one day before infection. LF (2 mg/ml), MUC1 (2 ug/ml) and α-LA (2 mg/ml) was mixed with SARS-CoV-2 pseudovirus (650 TCID50/well) at 4 ℃ for 1 h, respectively. The mixture was added into the cells and put at 4 ℃ for 2 h to allow viral attachment to cells. After washing out of free virus, the cells were incubated at 37 ℃ for 24 h. The luciferase assay was performed to detect SARS-CoV-2 pseudovirus infection.

Caco-2-N cells were incubated with trVLP (MOI=1) at 4 ℃ for 1h. Then, the cells were washed with PBS for 3 times. LF (2 mg/ml), MUC1 (2 ug/ml) and α-LA (2 mg/ml) were added into the media and incubated at 37 ℃ for 1h to allow viral internalization into cells, respectively. The mRNA of trVLP was measured by RT-qPCR. GFP were detected under a fluorescence microscope (ECHO laboratories, USA). For SARS-CoV-2 pseudovirus, the method was similar to the trVLP procedure and described as previously described . In detail, Vero E6 and Huh7.5 cells were seeded in a 24-well plate and then incubated with SARS-CoV-2 pseudovirus (650 TCID50/well) at 4 ℃ for 1 h. Then, the cells were washed with PBS for 3 times. LF (2 mg/ml), MUC1

(2 μg/ml) and α-LA (2 mg/ml) were added into the media and incubated at 37 ℃ for 1h

to allow viral internalization into cells, respectively. The luciferase assay was J o u r n a l P r e -p r o o f performed to detect SARS-CoV-2 pseudovirus infection.

Caco-2-N cells were infected with trVLP and incubated at 37 ℃ for 1h. After washing out of the free viruses, the cells were cultured in the media containing LF (2 mg/ml), MUC1 (2 ug/ml) and α-LA (2 mg/ml), respectively. Different time point of postinfection, the mRNA of trVLP was measured by RT-qPCR. GFP were detected by a fluorescence microscope (ECHO laboratories, USA). For SARS-CoV-2 pseudovirus, the method was described as previously described . In detail, Vero E6 and Huh7.5 cells were infected with SARS-CoV-2 pseudovirus (650 TCID50/well) and incubated at 37 ℃ for 1h. After washing out of the free viruses, the cells were cultured in the media containing LF (2 mg/ml), MUC1 (2 μg/ml) and α-LA (2 mg/ml), respectively. The luciferase assay was performed to detect SARS-CoV-2 pseudovirus infection.

The RNA extraction and quantification were performed as previously described . Briefly, Total RNA of cells was isolated with the RNAprep pure Cell Culture/Bacterial total RNA extraction kit (Tiangen biotech. Co., China). The cDNA was synthesized by RevertAid first strand cDNA synthesis kit (Invitrogen, USA). The qPCR for SARS-CoV-2 RNA was performed using the 2X RealStar Green Power Mixture (Genstar) according to the instruction. The qPCR primers for viral RNA were J o u r n a l P r e -p r o o f as follows: THU-2190 (5'-CGAAAGGTAAGATGGAGAGCC-3') and THU-2191 (5'-TGTTGACGTGCCTCTGATAAG-3'). GAPDH was used to normalize all the data .

Western blotting was performed as described previously . Briefly, cells were lysed with commercial RIPA buffer and centrifuged at 12,000 rpm at 4 ℃ for 30 min to extract the total protein. Cell lysates were loaded on the 12% SDS-PAGE gel and transferred to a polyvinylidene fluoride membrane. After blocking with blocking buffer with 5% milk, the membranes were incubated with antibodies. The antibody of anti-SARS-CoV-2 S protein against spike protein and anti-β-actin were used at 1:2000 dilutions. The second antibody of HRP-conjugated affinipure Goat anti-mouse IgG (H+L) were diluted at 1:20000. SuperSignal® West Femto Maximum Sensitivity Chemiluminescent Substrate (Thermo Scientific, USA) was used for signal development.

The influence of LF, MUC1 and α-LA on the affinity between ACE2 and SARS-CoV-2 S RBD was performed as previously described . Briefly, recombinant ACE-2 protein (Novoprotein, China) was immobilized on the MaxiSORP ELISA plate at 100ng per well in 50 μl of 100 mM carbonate-bicarbonate coating buffer over night at 4 ℃. HRP-conjugated SARS-CoV-2 RBD (Novoprotein, China) at final J o u r n a l P r e -p r o o f concentration of 1 ng/μl was mixed with serially diluted human breastmilk. LF, MUC1 and α-LA at different concentrations were added into the ACE-2-coated plate for 1h at room temperature, respectively. The absorbance reading at 450 nm and 570 nm were acquired using the Cytation 5 microplate reader (Bio Tek).

Statistical analyses were analyzed using GraphPad Prism 8 software (GraphPad Software Inc., San Diego, CA, USA). Data are presented as mean± SD and repeated at least three times (N = 3). Comparisons between the two groups were analyzed using the Student's t test. Values of p<0.05 was considered statistically significant, ns, p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 

Human breast milk: A review on its composition and bioactivity

Human milk composition: nutrients and bioactive factors

Evaluation for SARS-CoV-2 in breast milk from 18 infected women

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical

The role of the cell surface mucin MUC1 as a barrier to infection and regulator of inflammation

Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn

IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction

The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro

Antibacterial and antiviral effects of milk proteins and derivatives thereof

Detection of SARS-CoV-2 in human breastmilk

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Clinical characteristics of coronavirus disease 2019 in China

Decreasing the amount of trypsin in in-gel digestion leads to diminished chemical noise and improved protein identifications

A novel cell culture system modeling the SARS-CoV-2 life cycle

The biology of lactoferrin, an ironbinding protein that can help defend against viruses and bacteria

Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

An uninfected preterm newborn inadvertently fed SARS-CoV-2-positive breast milk

The cell surface mucin MUC1 limits the severity of influenza A virus infection

Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV

Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19

Purified human breast milk MUC1 and MUC4 inhibit human immunodeficiency virus

Lack of viral transmission to preterm newborn from a COVID-19 positive breastfeeding mother at 11 days postpartum

Expression profile of immune response genes in patients with severe acute respiratory syndrome

Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

Holder pasteurization of donated human milk is effective in inactivating SARS-CoV-2

Antiviral activities of lactoferrin

Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity

WHO frequently asked questions : breastfeeding and COVID-19 for health care workers

MUC1 and α-lactalbumin (α-LA) suppressed SARS-CoV-2 infection

LF and MUC1 inhibited viral attachment, entry and post-entry replication

LF and MUC1 impair SARS-CoV-2 to attach heparan sulfate proteoglycan

could also suppress SARS-CoV-2 variants infection

Mouse monoclonal anti-β-actin Proteintech Cat# 66009-1-Ig Goat Anti-Rabbit IgG(H+L)-HRP Conjugated EASYBIO Cat#

Goat Anti-Mouse IgG(H&L)-HRP Conjugated EASYBIO Cat#

Anti-2019-nCoV S-mIgG1 Antibody (8A5) Novoprotein Cat# DA035

Bacterial and virus strains SARS-CoV-2 pseudovirus (Luc) Youchun Wang's Lab

SARS-CoV-2 pseudovirus (GFP) Ningshao Xia's Lab

SARS-CoV-2 ΔN trVLP and mutants